180 related articles for article (PubMed ID: 21209397)
1. Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention.
Limburg PJ; Mahoney MR; Ziegler KL; Sontag SJ; Schoen RE; Benya R; Lawson MJ; Weinberg DS; Stoffel E; Chiorean M; Heigh R; Levine J; Della'Zanna G; Rodriguez L; Richmond E; Gostout C; Mandrekar SJ; Smyrk TC;
Cancer Prev Res (Phila); 2011 Feb; 4(2):259-69. PubMed ID: 21209397
[TBL] [Abstract][Full Text] [Related]
2. Differential preventive activity of sulindac and atorvastatin in Apc
Chang WL; Jackson C; Riel S; Cooper HS; Devarajan K; Hensley HH; Zhou Y; Vanderveer LA; Nguyen MT; Clapper ML
Gut; 2018 Jul; 67(7):1290-1298. PubMed ID: 29122850
[TBL] [Abstract][Full Text] [Related]
3. Randomized Phase II Trial of Polyphenon E versus Placebo in Patients at High Risk of Recurrent Colonic Neoplasia.
Sinicrope FA; Viggiano TR; Buttar NS; Song LMWK; Schroeder KW; Kraichely RE; Larson MV; Sedlack RE; Kisiel JB; Gostout CJ; Kalaiger AM; Patai ÁV; Della'Zanna G; Umar A; Limburg PJ; Meyers JP; Foster NR; Yang CS; Sontag S
Cancer Prev Res (Phila); 2021 May; 14(5):573-580. PubMed ID: 33648940
[TBL] [Abstract][Full Text] [Related]
4. Prevention of colonic neoplasia with polyethylene glycol: A short term randomized placebo-controlled double-blinded trial.
Wali RK; Bianchi L; Kupfer S; De La Cruz M; Jovanovic B; Weber C; Goldberg MJ; Rodriguez LM; Bergan R; Rubin D; Tull MB; Richmond E; Parker B; Khan S; Roy HK
PLoS One; 2018; 13(4):e0193544. PubMed ID: 29617381
[TBL] [Abstract][Full Text] [Related]
5. Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps.
Takayama T; Nagashima H; Maeda M; Nojiri S; Hirayama M; Nakano Y; Takahashi Y; Sato Y; Sekikawa H; Mori M; Sonoda T; Kimura T; Kato J; Niitsu Y
Clin Cancer Res; 2011 Jun; 17(11):3803-11. PubMed ID: 21385928
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase II trial of sulindac for lung cancer chemoprevention.
Limburg PJ; Mandrekar SJ; Aubry MC; Ziegler KL; Zhang J; Yi JE; Henry M; Tazelaar HD; Lam S; McWilliams A; Midthun DE; Edell ES; Rickman OB; Mazzone P; Tockman M; Beamis JF; Lamb C; Simoff M; Loprinzi C; Szabo E; Jett J;
Lung Cancer; 2013 Mar; 79(3):254-61. PubMed ID: 23261228
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of a leukotriene receptor antagonist in the treatment of human rectal aberrant crypt foci: a nonrandomized, open-label, controlled trial.
Higurashi T; Arimoto J; Ashikari K; Takatsu T; Misawa N; Yoshihara T; Matsuura T; Fuyuki A; Ohkubo H; Nakajima A
BMC Cancer; 2020 Aug; 20(1):770. PubMed ID: 32807113
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms.
Sinicrope FA; Velamala PR; Song LMWK; Viggiano TR; Bruining DH; Rajan E; Gostout CJ; Kraichely RE; Buttar NS; Schroeder KW; Kisiel JB; Larson MV; Sweetser SR; Sedlack RR; Sinicrope SN; Richmond E; Umar A; Della'Zanna G; Noaeill JS; Meyers JP; Foster NR
Cancer Prev Res (Phila); 2019 Nov; 12(11):821-830. PubMed ID: 31484660
[TBL] [Abstract][Full Text] [Related]
9. Eicosapentaenoic acid (EPA) efficacy for colorectal aberrant crypt foci (ACF): a double-blind randomized controlled trial.
Higurashi T; Hosono K; Endo H; Takahashi H; Iida H; Uchiyama T; Ezuka A; Uchiyama S; Yamada E; Ohkubo H; Sakai E; Maeda S; Morita S; Natsumeda Y; Nagase H; Nakajima A
BMC Cancer; 2012 Sep; 12():413. PubMed ID: 22992267
[TBL] [Abstract][Full Text] [Related]
10. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial.
Hosono K; Endo H; Takahashi H; Sugiyama M; Sakai E; Uchiyama T; Suzuki K; Iida H; Sakamoto Y; Yoneda K; Koide T; Tokoro C; Abe Y; Inamori M; Nakagama H; Nakajima A
Cancer Prev Res (Phila); 2010 Sep; 3(9):1077-83. PubMed ID: 20810669
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
12. Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma.
Thompson PA; Wertheim BC; Zell JA; Chen WP; McLaren CE; LaFleur BJ; Meyskens FL; Gerner EW
Gastroenterology; 2010 Sep; 139(3):797-805, 805.e1. PubMed ID: 20538001
[TBL] [Abstract][Full Text] [Related]
13. Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention.
Xiao H; Yang CS
Int J Cancer; 2008 Sep; 123(5):983-90. PubMed ID: 18548583
[TBL] [Abstract][Full Text] [Related]
14. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
15. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.
Bjarnadottir O; Romero Q; Bendahl PO; Jirström K; Rydén L; Loman N; Uhlén M; Johannesson H; Rose C; Grabau D; Borgquist S
Breast Cancer Res Treat; 2013 Apr; 138(2):499-508. PubMed ID: 23471651
[TBL] [Abstract][Full Text] [Related]
16. Dysplastic Aberrant Crypt Foci: Biomarkers of Early Colorectal Neoplasia and Response to Preventive Intervention.
Clapper ML; Chang WL; Cooper HS
Cancer Prev Res (Phila); 2020 Mar; 13(3):229-240. PubMed ID: 32132117
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the prevalence and number of aberrant crypt foci associated with human colorectal neoplasm.
Sakai E; Takahashi H; Kato S; Uchiyama T; Hosono K; Endo H; Maeda S; Yoneda M; Taguri M; Nakajima A
Cancer Epidemiol Biomarkers Prev; 2011 Sep; 20(9):1918-24. PubMed ID: 21750169
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of aspirin and metformin combination therapy in patients with rectal aberrant crypt foci: a double-blinded randomized controlled trial.
Higurashi T; Arimoto J; Ashikari K; Takatsu T; Misawa N; Yoshihara T; Matsuura T; Fuyuki A; Ohkubo H; Nakajima A
BMC Cancer; 2020 Oct; 20(1):1043. PubMed ID: 33121471
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
[TBL] [Abstract][Full Text] [Related]
20. The Effect of Low Doses of Acetylsalicylic Acid on the Occurrence of Rectal Aberrant Crypt Foci.
Kowalczyk M; Sigorski D; Dyśko Ł; Zieliński E; Zupanovich Lucka D; Klepacki Ł
Medicina (Kaunas); 2022 Nov; 58(12):. PubMed ID: 36556972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
